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signiﬁcance of that truncation has not been explored. In an attempt to elucidate if GSK3
truncation has a pathophysiological relevance, we have used intraperitoneal injections of
kainic acid (KA) in rats and intra-amygdala KA microinjections in mice as in vivo models of
excitotoxicity. Spectrin cleavage analyzed by immunohistochemistry was observed in the
CA1 hippocampal ﬁeld in KA-intraperitoneal treated rats while the CA3 region was the
hippocampal area affected after intra-amygdala KA microinjections. GSK3β immunoﬂuor-
escence did not colocalize with truncated spectrin in both treatments using an antibody
that recognize the N-terminal end of GSK3β. Thus, those neurons which are spectrin-
positive do not show GSK3β immunolabelling. To study GSK3β truncation in vitro, we
exposed organotypic hippocampal slices and cultured cortical neurons to KA leading to the
truncation of GSK3 and we found that truncation was blocked by the calpain inhibitor
calpeptin. These data suggest a relationship between N-terminal GSK3β truncation and
excitotoxicity. Overall, our data reinforces the important relationship between glutamate
receptors and GSK3 and their role in neurodegenerative processes in which excitotoxicity
is involved.
& 2015 Elsevier B.V. All rights reserved.6
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GSK3 (Glycogen synthase kinase-3) is a kinase with two isoforms
in mammals, GSK3α with a molecular weight of 51 kDa and
GSK3βwith a molecular weight of 47 kDa (Woodgett, 1990). GSK3
can phosphorylate a variety of substrates including cytoskeletal
proteins, transcription factors and metabolic regulators. Thus,
GSK3 plays important roles in embryonic development, cell
differentiation, microtubule dynamics, cell cycle division, cell
adhesion, glucose metabolism and apoptosis. Deregulation of
GSK3 activity is believed to play a key role in the pathogenesis of
chronic central nervous system disorders such as Alzheimer
disease (AD), bipolar disorder and Huntington disease, as well as
in metabolic disorders such as type II diabetes (Beurel et al., 2014;
Hernandez and Avila, 2008; Jope and Johnson, 2004).
GSK3 is regulated by different mechanisms. One of these
mechanisms is phosphorylation. Phosphorylation at Tyr-279/216
of GSK3α/β is necessary for its activation (Hughes et al., 1993). In
contrast, inactivation of GSK3α/β is achieved by phosphorylation
at Ser21/9, via a mechanism that involves the binding of a small
loop containing the phosphorylated serine back to the substrate-
binding site on the enzyme (for a review see (Beurel et al., 2014).
Another important mechanism controlling GSK3 function is
through sequestration, as subcellular localization of GSK3 reg-
ulates substrates accessibility. GSK3 is observed in cytosol,
mitochondria and nucleus, and also found enriched in speciﬁc
neuronal compartments such as dendritic spines (Bijur and Jope,
2003; Jope and Johnson, 2004; Peineau et al., 2007). Therefore,
restricting GSK3 to speciﬁc compartments may affect respon-
siveness to different signals. On the other hand, GSK3 can be
regulated through binding to other proteins in several multi-
protein complexes. The most studied pathway involving GSK3
complex formation is regulated by Wnt (Beurel et al., 2014).
Recently, a novel mechanism of regulation has been
described: cleavage of GSK3 by calpain (Goni-Oliver et al., 2007;
Ma et al., 2012). Cultured cortical neurons exposed to ionomycin,
glutamate or N-methyl-D-aspartate (NMDA) led to the truncation
of GSK3 (Goni-Oliver et al., 2007; Ma et al., 2009) as well as
hippocampal cells exposed to 3-nitropropionic acid (Crespo-Biel
et al., 2010b). However, the in vivo generation of that truncation
has not been analyzed. In an attempt to elucidate if that
truncation has a pathophysiological relevance, we have used
two in vivo models of excitotoxicity employing intra-peritoneal
kainic acid (KA)-injections in rats and intra-amygdala KA micro-
injections in mice. The work presented here demonstrates that
in excitotoxicity conditions GSK3 suffers a process of proteolysis.IB: Anti-Nt-GSK3β
Fig. 1 – Characterization of Nterminal-GSK3β antibody.
(A) Schematic diagrams of FLAG-GSK3β forms used showing
the epitopes recognized by the GSK3 antibodies. The calpain
cleavage sites are shown. (B) COS-7 cells were transfected
with pcDNA3 (MOCK), rat Wt-GSK3β (WT), rat ΔC-GSK3β (ΔC)
and rat ΔN-GSK3β (constructs terminally FLAG-tagged) using
Lipofectamine 2000. The samples were immunoblotted with
the anti-FLAG antibody, anti-GSK3α/β antibody, anti-pSer9/
21-GSK3α/β and anti-Nt-GSK3β antibody. The results show
as Nt-GSK3β antibody recognizes full-length kinase and
ΔC-GSK3β, but does not recognize N-terminal
truncated form.2. Results
2.1. Characterization of Nterminal-GSK3β antibody
To analyze GSK3β truncation in biological samples, we ﬁrst
characterized an antibody which is able to recognize full-length
GSK3β but unable to recognize N-terminal truncated form. The
anti-Nterminal-GSK3β monoclonal antibody was produced by
immunizing animals with a synthetic peptide corresponding to
the sequence of human GSK3β around aminoacid 22 (Cell
Signaling, reference 9315). COS-7 cells were transfected with ratWt-GSK3β, ΔC-GSK3β (aminoacids 1-384) and ΔN-GSK3β (ami-
noacids 39-420) constructs and extracts tested with several GSK3
antibodies. Fig. 1 shows as anti-Nterminal-GSK3β antibody
recognizes full-length kinase and Cterminal-GSK3β truncated
form, but does not recognize N-terminal truncated GSK3β.
2.2. Kainic acid induces GSK3 truncation in the
hippocampus of rats and mice
We ﬁrst analyzed hippocampal samples by western blotting with
anti-GSK3 antibody to determine whether GSK3 truncation was
taking place after KA-i.p. treatment in rats. Upon treatment,
additional GSK3 immunoreactive protein bands appeared at a
lower molecular weight, reaching a maximum at 24 h (Fig. 2).
These bands were only observed in overexposed gels, suggesting
that their concentration was low. These bands were not detected
in extracts prepared from saline-treated rats. We have previously
described similar fragments in primary neuronal cultures after
NMDA activation and shown this to be mediated by calpain
(Goni-Oliver et al., 2007). Accumulation of alpha II spectrin
fragments is a well characterized process associated with calpain
activation (Czogalla and Sikorski, 2005). Fig. 2 shows the genera-
tion of lower molecular weight spectrin fragments in KA-i.p.
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Fig. 2 – GSK3 truncation in response to i.p. KA-induced neurotoxicity. (A) Adult male wistar rats injected with KA or saline
were sacriﬁced at various time points after injection. GSK3 and spectrin truncation was assessed by western blotting. Equal
amounts of hippocampal extracts (15 lg) were tested after 3, 7 or 24 h with anti-GSK3α/β and anti-spectrin. Truncated GSK3-
forms were only seen in overexposed autoradiograms. A less exposed autoradiogram for anti-GSK3α/β is also shown.
Quantization of GSK3 and spectrin truncated forms after 24 h of treatment is shown in (B). Data are mean7SD from n¼3 per
group. npo0.05 versus control samples. Molecular weights are shown in A. Arrow head indicates GSK3-truncated band
quantiﬁed in B.
b r a i n r e s e a r c h 1 6 1 1 ( 2 0 1 5 ) 8 4 – 9 286spectrin truncation was taking place. The 145 kDa band is a
marker of calpain activation (Zhang et al., 2009). To analyze in
which cells GSK3 truncation occurred we used the previously
characterized antibody which recognizes the N-terminal end of
GSK3β (Fig. 1). GSK3β is truncated at its N- and C-terminal ends at
residues Thr-38-Thr-39 and Ile-384-Gln-385 (Ma et al., 2012).
Thus, an antibody which recognizes the epitope around Ala22
does not recognize N-terminal truncated fragment generated
indicating that the enzyme is N-terminal truncated. To deter-
mine if both truncated proteins, spectrin and GSK3, colocalize we
performed immunoﬂuorescence studies to show if those neu-
rons that are labeled by alpha II spectrin antibody are the same
that display N-terminal GSK3 truncation. Double immunostain-
ing with anti-Nterminal-GSK3β antibody and anti-spectrin
showed that in control rats anti-Nterminal-GSK3β antibody
labeled CA1, CA2 and CA3 areas without spectrin immunoreac-
tivity (Fig. 3A). In 24 h KA-i.p. treated rats anti-Nterminal-GSK3β
antibody signal disappeared and strong spectrin labeling can be
observed in CA1 area (Fig. 3B). This region is the main hippo-
campal area affected in KA-i.p. treated rats (Araujo et al., 2008).
Anti-Nterminal-GSK3β antibody labeled some cells in CA1 region,
but these cells did not colocalize with cleaved spectrin labeled
cells (Fig. 3C). These cells probably represent those cells where
proteases are activated and where spectrin fragments accumu-
late. In good agreement, cells that were negative for spectrin
were labeled by anti-Nterminal-GSK3β antibody (Fig. 3C).
In order to see if in another animal model of excitotoxicity
produced the same GSK3 truncation we analyzed this
response in mice. Taking into account that mouse strains
vary signiﬁcantly in their sensitivity to KA-induced neurode-
generation (Yang et al., 2005), we decided to analyze this
response in mice that received an intra-amygdala injection ofKA a model of focally-evoked seizure-induced neuronal death
using intra-amygdala KA microinjection and characterized by
an acute hippocampal pathology (Mouri et al., 2008).
Intra-amygdala KA injection in mice results, after 4 h, in
damage that mainly affects the CA3 region (Mouri et al.,
2008). When we analyzed samples from these mice, spectrin
truncation was detected in the CA3 region and a decrease in
GSK3β levels determined with the anti-Nterminal-GSK3β anti-
body was also observed only in that region (Fig. 4).
Thus, in two in vivo models of KA-induced hippocampal
damage a decrease in Nterminal-GSK3 levels and an increase
in spectrin truncation were observed. To analyze in more
detail that effect we next carried out in vitro studies.
2.3. Kainic acid induces GSK3 truncation in organotypic
hippocampal cultures
Given the role played by KA in GSK3 truncation in rodents, we
explored whether kainate could be responsible for this GSK3
regulation in organotypic hippocampal cultures which reﬂect
events happening in the hippocampus. Thus, we added KA
(50 mM) to these cultures and we analyzed those samples by
western-blot. Fig. 5 shows that after 7 h of treatment, there
was an increase not only in spectrin truncation but also in
GSK3 truncation, and those proteolytic processes were inhib-
ited by calpeptin (10 mM), a calpain inhibitor.
2.4. Kainic acid induces GSK3 truncation in neuronal
primary cultures
Then, we treated neuronal primary cultures with KA. Treat-
ment of cultured cortical neurons with KA (50 μM) induced
Fig. 3 – Spectrin and truncated GSK3β levels in rats treated i.p. with kainate. Representative confocal photomicrographs of
hippocampal changes for spectrin (green) and Ntruncated GSK3β (red) in control rats (A) and KA treated rats (B) in CA1, CA2
and CA3 hippocampal regions. Images were taken from the same slice. CA2 and CA3 regions did not show differences among
control and KA treated mice while CA1 area shows an increase in spectrin positive cells and a decrease in Nt-GSK3β signaling.
(C) High magniﬁcation image of sample of KA treated rats of CA1 region. It should be noted that no colocalization of spectrin
(green) and Nt-GSK3β (red) is observed.
Fig. 4 – Spectrin and truncated GSK3β levels in intra-amygdala KA injected mice Representative confocal photomicrographs of
hippocampal changes for spectrin (green) and Ntruncated GSK3β (red) antibodies in 4 h control and KA treated mice in
hippocampal regions. CA1 and CA2 regions did not show differences among control and KA treated mice while CA3 area
shows an increase in spectrin positive cells and a decrease in Nt-GSK3β signaling.
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Fig. 5 – KA induces GSK3 and spectrin truncation in organotypic hippocampal slice cultures. Slices were treated with 50 μMKA
or vehicle (CON). Protein extracts (15 μg) of slices treated with KA for 1, 3 or 7 h in the presence or absence of 10 lM calpeptin
(CALP) were immunoblotted with the antibody that recognizes spectrin (A) and anti-GSK3α/β antibody (C). Quantiﬁcation of the
truncated spectrin fragments (B) and the 40-kDa GSK3 truncated form (D) are shown. Bars, media7SD. *po0.05 versus control.
Arrow head indicates GSK3-truncated band quantiﬁed in D.
b r a i n r e s e a r c h 1 6 1 1 ( 2 0 1 5 ) 8 4 – 9 288GSK3 truncation in a time-dependent manner (Fig. 6A) and
was dose-dependent (EC50¼1.8170.95 μM) (Fig. 6B). The kai-
nate effect was mediated by calpain as evidenced by the fact
that calpeptin (10 μM) prevented the formation of the 40 kDa
truncated form (Fig. 6C). The CDK5 regulator subunit p35, a
well-known calpain substrate (Kusakawa et al., 2000), showed
a similar pattern of protolysis, giving rise to the truncated p25
form (Fig. 6B). In addition, processing of full-length spectrin
into break-down products denoted the activation of calpain.
Thus, the EC50 for kainic acid induced alpha II spectrin
truncation was 1.1470.87 μM, similar to the EC50 obtained
for GSK3-truncation. In addition, proteolysis of alpha II
spectrin by calpain produces 150 and 145 breakdown pro-
ducts while caspase 3 produces a different 150 kDa break-
down fragments (Zhang et al., 2009). Calpeptin inhibited the
generation of the 145 kDa fragment in cultured neurons while
the 150 KDa was highly decreased suggesting that alpha II
spectrin is substrate of calpain but there is also some
contribution by caspase 3. However, the calpain inhibitor
calpeptin inhibited GSK3 truncation in cultured neurons and
hippocampal slices suggesting that GSK3 is substrate of
calpain only.
The antibody which recognize the epitope around Ala22
(Fig. 1) does not recognize any truncated fragment generated
in KA-induced cultures suggesting that the N-terminal end
was removed by calpain (Fig. 6C). Indeed, the antibody that
does not recognize the truncated form is able to detect thetwo full-length GSK3β isoforms generated by alternative
splicing (Mukai et al., 2002). We next addressed whether the
GSK3 truncation by calpain after stimulation of kainate
receptors could be observed in the presence of an extracel-
lular calcium chelator as EGTA (5 mM, Fig. 6D). Activation of
the kainate receptors in the presence of extracellular EGTA
led to inhibition of GSK3 proteolysis as was previously
described for NMDA receptors (Goni-Oliver et al., 2009). These
data suggest that extracellular calcium inﬂux into cortical
neurons caused by kainate receptors increase GSK3 trunca-
tion through calpain activation.3. Discussion
Altered calcium homeostasis along with activation of calpain
contributes to neuronal degeneration by cleavage of speciﬁc
substrates that have crucial roles in neuronal survival
(Camins et al., 2006; Huang and Wang, 2001; Patrick et al.,
1999), including protein kinases (Goll et al., 2003). Previous
studies have shown that GSK3 can undergo a limited proteo-
lysis in cultured neurons (Crespo-Biel et al., 2010b; Czogalla
and Sikorski, 2005; Feng et al., 2013; Goni-Oliver et al., 2007;
Ma et al., 2012, 2009). However, it has been unclear whether
this truncation of GSK3 occurs in vivo. In the present study we
provide in vivo evidence that during KA-induced neuroexci-
totoxicity, GSK3 is proteolytically truncated by calpain. In
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Fig. 6 – Proteolysis of GSK3 in cortical neurons treated with kainate. (A) Cortical neurons (DIV12) were treated with KA (50 lM)
or vehicle for 3, 5 or 7 h. The samples were immunoblotted with the antibody that recognizes spectrin and the anti-GSK3α/β
antibody. The generation of a 40-kDa GSK3 truncated form as well as the truncated spectrin fragments (150 and 145 kDa) is
shown by the arrows. (B) Cortical neurons were treated with growing concentrations of KA for 5 h. The samples were
immunoblotted with the anti-GSK3α/β antibody. The generation of a 40-kDa GSK3 truncated form is shown by the head arrow.
The same samples were also immunoblotted with the anti-p35/p25 antibody and the antibody that recognizes spectrin.
(C) Neurons were treated with 50 μM KA in the presence or absence of the calpain inhibitor calpeptin (50 μM, CALP) for 5 h and
immunobloted with anti-spectrin, anti-GSK3α/β antibody and the anti-Nterminal-GSK3β antibodies. Arrows show the 150 and
145 kDa of spectrin fragments as well as truncated GSK3 fragment (D) Extracellular EGTA (5 mM) inhibits KA-induced
truncation (50 lM, 5 h treatment). Arrow head indicates GSK3-truncated band.
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the hippocampus in two animal models. Then, by using
oganotypic hippocampal cultures and neuronal primary cul-
tures we demonstrated that this is mediated by calpain.
In rats, systemic KA is a common model to study neuronal
excitotoxicity. That model produce extensive damage, being the
CA1 area the hippocampal region more affected (Araujo et al.,
2008). In addition, and taking into account that mouse strains
vary signiﬁcantly in their sensitivity to KA-i.p. induced neuro-
degeneration (Yang et al., 2005), intra-amygdala injection of KA
is a well characterized model of neuronal death in mice, being
the CA3 hippocampal region the area predominantly damaged
(Mouri et al., 2008). In both animal models of excitotoxicity we
observed a decrease in Nterminal GSK-3 labeling suggesting
that KA-induced neurodegeneration provokes GSK3 truncation
in vivo and more important in those areas that are mainly
affected in both models.
Proteases of the calpain and caspase families are involved
in neurodegeneration mediated by calcium inﬂux. Proteolysis
of alpha II Spectrin by calpain produces 150 and 145 kDa
breakdown products while caspase 3 produces a different150 kDa fragments (Zhang et al., 2009). In organotypic cul-
tures as well as in cultured neurons, calpeptin inhibited the
generation of the 145 kDa fragment while the 150 KDa was
highly decreased suggesting that alpha II Spectrin is substrate
of calpain but also caspase 3. However, the calpain inhibitor
calpeptin inhibits GSK3 truncation in cultured neurons and
hippocampal slices suggesting that GSK3 is substrate only of
calpain. In fact, it has been reported that the caspase-3
inhibitor Z-VAD-FMK does not prevent the generation of
GSK3 truncated fragments in rat cerebellar granule neurons
(Ma et al., 2012). In addition, in the same KA injected rat
model, caspases are not involved in GSK3 decreased levels
(Araujo et al., 2008).
N-terminal truncation eliminates the regulatory domain that
inhibits the catalytic activity (Goni-Oliver et al., 2007; Ma et al.,
2012). Thus, the present results seem to propose that during
excitotoxicity processes there is an increase in GSK3 activity.
We have not analyzed that increase; however, our results do
allow us to state that during the excitotoxic process total GSK3
level decreased in cultured neurons. Interestingly, the 40 kDa-
truncated form does not accumulate, suggesting that when
b r a i n r e s e a r c h 1 6 1 1 ( 2 0 1 5 ) 8 4 – 9 290GSK3 is truncated by calpain, a short lived product is formed
that is rapidly degraded. What is the physiological signiﬁcance
of our results? It is interesting to note that lithium has a
neuroprotective effect in KA-treated rats (Busceti et al., 2007;
Crespo-Biel et al., 2010a). However, despite the neuroprotective
effect of GSK3 inhibition, constitutive knock-out mice show
embryonic lethality (Hoeﬂich et al., 2000). In this regard,
pharmacological inhibition of GSK3 in cell lines has also been
shown to facilitate apoptosis (Beurel and Jope, 2006) (Beyaert
et al., 1989). Furthermore, transgenic mice with expression of a
dominant negative form of GSK3β showed that a reduction in
GSK3 activity induces apoptosis in neurons (Gomez-Sintes et al.,
2007). Our data seem to suggest that in excitotoxic situations,
likely due to an increase in cytosolic calcium and calpain
activation, those cells that are spectrin positives are suffering
a decrease in GSK3 levels. Interestingly, an overexpression of
GSK3β truncated forms in rat cerebellar granule neurons gen-
erated by calpain induces apoptosis as well (Ma et al., 2012).
A special feature of our work is the characterization of an
antibody which is able to recognize full-length GSK3β but
unable to recognize N-terminal truncated form. Calpain
cleaves GSK3β in vitro not only at the N-terminal (at residues
Thr-38-Thr-39) but also at the C-terminal end (at residues Ile-
384-Gln-385) (Ma et al., 2012). However, our results suggest
that C-terminal truncation does not take place in KA treated
neurons. The anti-Nterminal-GSK3β monoclonal antibody
used is not able to recognize any band of lower molecular
weight (Fig. 5C), although it recognized the isoform
C-terminal truncated (Fig. 1) and the full-length isoforms of
GSK3β (Fig. 5C) (Mukai et al., 2002). However, it cannot be
discard that C-truncated form could be a short life fragment
or that, as has been described previously, high levels of Ser-
389 phosphorylation of GSK3 cold inhibits C-terminal clea-
vage (Ma et al., 2012).4. Conclusions
To summarize, the present results have clear implications in
all the transduction pathways in which GSK3 is involved.
Taking into account that calpains induce p35 truncation and
that calpain also induces GSK3 truncation, it is possible that
the deregulation of calcium homeostasis may contribute to
neuropathology through the calpain/CDK5/GSK3 system.
Thus, our data support the view that calpains may provide
a link between both kinases and provide cues for the under-
standing of GSK3 involvement in neurodegenerative pro-
cesses where excitotoxicity conditions are present.5. Experimental procedures
5.1. Animals and tissue processing.
5.1.1. Animal care
Rats (Wistar, 2 months) and mice (C57BL/6J, 1 month) were
treated following the guidelines of Council of Europe Con-
vention ETS123, revised as indicated in the Directive 86/609/
EEC. In addition all protocols were approved by the institu-
tional animal care and use committee. Animals were bred atthe Centro de Biología Molecular “Severo Ochoa” (Madrid, Spain)
and were kept on a normal light-dark cycle (12 h light/12 h
dark), with free access to food and water.
5.1.2. Kainic acid treatments
KA was dissolved in saline and rats were injected intraper-
itoneally at 10 mg/kg body weight and monitored for respon-
siveness to KA. Intra-amygdala KA injections were performed
according to a previously described technique and killed 4 h
later (Mouri et al., 2008).
5.1.3. Tissue processing
Animals were sacriﬁced using CO2 inhalation and the brains
were removed, post-ﬁxed overnight in 4% PFA and 30 μm
sagittal sections were obtained on a cryostat.
5.2. Primary cultures
Primary cultures of mouse cortical neurons were prepared accord-
ing to modiﬁcations of established procedures (Hernandez et al.,
2004). Brieﬂy, mouse pups were sacriﬁced at postnatal day 1.
Cortical tissue was then dissected and dissociated individually
from each pup with the papain dissociation system (Worthington
Biochemical Corp.). Cortical neurons were maintained in neuro-
basal medium (Invitrogen) supplemented with 1% B-27, 5% fetal
calf serum, 0.5mM glutamine, 100 units/ml penicillin, and
100mg/ml streptomycin and grown on 3 μg/ml laminin (Sigma)
and 10 μg/ml poly-L-lysine-coated cover plates. The cells were
incubated in 95% air, 5% CO2 in a humidiﬁed incubator at 37 1C.
Cytosine arabinoside (2.5 μM) was added to cultures on the second
day after seeding (DIV3) to inhibit the proliferation of non-
neuronal cells. Cells were used for experiments at DIV12.
5.3. Transfection of COS-7 cell
COS-7 transfection studies were carried out using constructs
kindly provided by Dr Mingtao Li, Sun Yat-sen University, China
(Ma et al., 2012). The rat Wt-GSK3β, ΔC-GSK3β (aminoacids 1-384)
and ΔN-GSK3β (aminoacids 39-420) constructs are N-terminally
FLAG-tagged and cloned into pcDNA3.1 vector. COS-7 cells were
transfected using Lipofectamine 2000 (Invitrogen) according to
the manufacturer's instructions.
5.4. Organotypic hippocampal slice cultures
Hippocampal slice cultures were prepared from 1 mouth-old
C57BL/6J mice. Animals were decapitated; the brains were
removed and transferred to cold Minimal Essential Medium
(MEM). A tissue chopper was used to cut hippocampal slices
(400 mm), which were placed on porous 0.4 mm membranes
(Millipore). The membranes were then transferred to culture
plates covered with culture medium (Neurobasal Medium
supplemented 5% horse serum and B27). The culture medium
was changed two times per week. Slice cultures were used for
experiments after 7 days in vitro.
5.5. Western blot analysis
Brains were quickly dissected on an ice-cold plate. Hippo-
campus was isolated and extracts for western blot analysis
b r a i n r e s e a r c h 1 6 1 1 ( 2 0 1 5 ) 8 4 – 9 2 91were prepared by homogenizing in ice-cold extraction buffer
consisting of 50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% NP-40,
1 mM sodium orthovanadate, 1 mM EDTA, a protease inhibi-
tor cocktail (Roche) and 1 mM Okadaic acid (phosphatase
inhibitor). The samples were homogenized and protein con-
tent was determined by Bradford. Thirty micrograms of total
protein were electrophoresed on 10% SDS-polyacrylamide gel
and transferred to a nitrocellulose membrane (Schleicher and
Schuell, Keene, NH). The experiments were performed using
the following primary monoclonal antibodies: anti-GSK3α/β
(1/1000, BD Transduction Laboratories), anti-p21/9- GSK3α/β
(1/500, Cell Signaling), anti-Nterminal-GSK3β (1/1000, refer-
ence 9315 Cell Signaling), anti-spectrin (1/1000, Chemicon
International), anti-p35/25 (1/500, Santa Cruz), anti-FLAG
(1/5000, Sigma) and anti-actin (1/5000, Sigma). Filters were
incubated with the antibody at 4 1C overnight in 5% nonfat
dried milk. Secondary goat anti-mouse and anti-rabbit anti-
bodies (1/1000; Invitrogen, San Diego, CA) and ECL detection
reagents (Amersham Biosciences, Arlington Heights, IL) were
used for immunodetection. Quantiﬁcation was performed
by densitometric scanning. The densitometry values were
obtained in the linear range of detection with these anti-
bodies. These values were normalized with respect to the
values obtained with an anti-β-actin antibody to correct for
total protein content.
5.6. Immunostaining
For immunoﬂuorescence, immunostaining was carried out
following a standard procedure. Sections were incubated with
the primary antibody overnight at 4 1C in a PB solution
containing BSA 1% and TritonX-100 1%. Primary antibodies
were: anti-GSK3αβ (1/100), anti-Nterminal-GSK3β (1/100) and
anti-spectrin (1/100). After washing with blocking solution
3 times, sections were incubated with donkey Alexa-
conjugated secondary antibodies (anti-rabbit, anti-mouse
Alexa-Fluor 488/555-conjugated) overnight at 4 1C (1:1,000)
(Molecular Probes, Millipore). Finally, after washing with
phosphate buffer solution, sections were incubated with DAPI
(1/2,000) (Calbiochem) for 10 min. Images are single sections
of a z-series acquiring each channel in a sequential mode
using an inverted Zeiss LSM710 confocal microscope with a
63X/1.40 Plan-Apochromatic objective.
5.7. Statistical analysis
The SPSS 17.0.1 softwaSigmaPlot 12.5 software was used for
EC50 experiments were carried out in triplicate. Student t test
was used for single comparisons.Acknowledgments
Our laboratory is funded by grants from Ministerio de Educa-
ción y Ciencia (SAF2010-15525 and BUF2013-40664-P) and
Comunidad de Madrid (S2010/BMD-2331). We also acknowl-
edge institutional support from Fundación Ramón Areces.
The authors would also like to thank the Health Research
Board Ireland for support (PD/2009/31 to TE and HRA_POR/
2011/41 to DCH).r e f e r e n c e s
Araujo, I.M., Gil, J.M., Carreira, B.P., Mohapel, P., Petersen, A.,
Pinheiro, P.S., Soulet, D., Bahr, B.A., Brundin, P., Carvalho, C.M.,
2008. Calpain activation is involved in early caspase-
independent neurodegeneration in the hippocampus
following status epilepticus. J. Neurochem. 105, 666–676.
Beurel, E., Jope, R.S., 2006. The paradoxical pro- and anti-
apoptotic actions of GSK3 in the intrinsic and extrinsic
apoptosis signaling pathways. Prog. Neurobiol. 79, 173–189.
Beurel, E., Grieco, S.F., Jope, R.S., 2014. Glycogen synthase kinase-3
(GSK3): regulation, actions, and diseases. Pharmacol. Ther..
Beyaert, R., Vanhaesebroeck, B., Suffys, P., Van Roy, F., Fiers, W.,
1989. Lithium chloride potentiates tumor necrosis factor-
mediated cytotoxicity in vitro and in vivo. Proc. Natl. Acad. Sci.
USA 86, 9494–9498.
Bijur, G.N., Jope, R.S., 2003. Glycogen synthase kinase-3 beta is
highly activated in nuclei and mitochondria. Neuroreport 14,
2415–2419.
Busceti, C.L., Biagioni, F., Aronica, E., Riozzi, B., Storto, M.,
Battaglia, G., Giorgi, F.S., Gradini, R., Fornai, F., Caricasole, A.,
Nicoletti, F., Bruno, V., 2007. Induction of the Wnt inhibitor,
Dickkopf-1, is associated with neurodegeneration related to
temporal lobe epilepsy. Epilepsia 48, 694–705.
Camins, A., Verdaguer, E., Folch, J., Pallas, M., 2006. Involvement
of calpain activation in neurodegenerative processes. CNS
Drug Rev. 12, 135–148.
Crespo-Biel, N., Camins, A., Canudas, A.M., Pallas, M., 2010a.
Kainate-induced toxicity in the hippocampus: potential role of
lithium. Bipolar Disord. 12, 425–436.
Crespo-Biel, N., Camins, A., Gutierrez-Cuesta, J., Melchiorri, D.,
Nicoletti, F., Pallas, M., Canudas, A.M., 2010b. Regulation of
GSK-3beta by calpain in the 3-nitropropionic acid model.
Hippocampus 20, 962–970.
Czogalla, A., Sikorski, A.F., 2005. Spectrin and calpain: a ‘target’
and a ‘sniper’ in the pathology of neuronal cells. Cell. Mol. Life
Sci. 62, 1913–1924.
Feng, Y., Xia, Y., Yu, G., Shu, X., Ge, H., Zeng, K., Wang, J., Wang, X.,
2013. Cleavage of GSK-3beta by calpain counteracts the
inhibitory effect of Ser9 phosphorylation on GSK-3beta
activity induced by H2O2. J. Neurochem. 126, 234–242.
Goll, D.E., Thompson, V.F., Li, H., Wei, W., Cong, J., 2003. The
calpain system. Physiol. Rev. 83, 731–801.
Gomez-Sintes, R., Hernandez, F., Bortolozzi, A., Artigas, F., Avila,
J., Zaratin, P., Gotteland, J.P., Lucas, J.J., 2007. Neuronal
apoptosis and reversible motor deficit in dominant-negative
GSK-3 conditional transgenic mice. EMBO J. 26, 2743–2754.
Goni-Oliver, P., Lucas, J.J., Avila, J., Hernandez, F., 2007. N-terminal
cleavage of GSK-3 by calpain: a new form of GSK-3 regulation.
J. Biol. Chem. 282, 22406–22413.
Goni-Oliver, P., Avila, J., Hernandez, F., 2009. Memantine inhibits
calpain-mediated truncation of GSK-3 induced by NMDA:
implications in Alzheimer’s disease. J. Alzheimers Dis. 18,
843–848.
Hernandez, F., Perez, M., Lucas, J.J., Mata, A.M., Bhat, R., Avila, J.,
2004. Glycogen synthase kinase-3 plays a crucial role in tau
exon 10 splicing and intranuclear distribution of SC35.
Implications for Alzheimer’s disease. J. Biol. Chem. 279,
3801–3806.
Hernandez, F., Avila, J., 2008. The role of glycogen synthase kinase
3 in the early stages of Alzheimers’ disease. FEBS Lett. 582,
3848–3854.
Hoeflich, K.P., Luo, J., Rubie, E.A., Tsao, M.S., Jin, O., Woodgett, J.R.,
2000. Requirement for glycogen synthase kinase-3beta in cell
survival and NF-kappaB activation. Nature 406, 86–90.
Huang, Y., Wang, K.K., 2001. The calpain family and human
disease. Trends Mol. Med. 7, 355–362.
b r a i n r e s e a r c h 1 6 1 1 ( 2 0 1 5 ) 8 4 – 9 292Hughes, K., Nikolakaki, E., Plyte, S.E., Totty, N.F., Woodgett, J.R.,
1993. Modulation of the glycogen synthase kinase-3 family by
tyrosine phosphorylation. EMBO J. 12, 803–808.
Jope, R.S., Johnson, G.V., 2004. The glamour and gloom of
glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95–102.
Kusakawa, G., Saito, T., Onuki, R., Ishiguro, K., Kishimoto, T.,
Hisanaga, S., 2000. Calpain-dependent proteolytic cleavage of
the p35 cyclin-dependent kinase 5 activator to p25. J. Biol.
Chem. 275, 17166–17172.
Ma, S., Liu, S., Huang, Q., Xie, B., Lai, B., Wang, C., Song, B., Li, M.,
2012. Site-specific phosphorylation protects glycogen
synthase kinase-3beta from calpain-mediated truncation of
its N and C termini. J. Biol. Chem. 287, 22521–22532.
Ma, T., Zhao, Y., Kwak, Y.D., Yang, Z., Thompson, R., Luo, Z., Xu,
H., Liao, F.F., 2009. Statin’s excitoprotection is mediated by
sAPP and the subsequent attenuation of calpain-induced
truncation events, likely via rho-ROCK signaling. J. Neurosci.
29, 11226–11236.
Mouri, G., Jimenez-Mateos, E., Engel, T., Dunleavy, M., Hatazaki,
S., Paucard, A., Matsushima, S., Taki, W., Henshall, D.C., 2008.
Unilateral hippocampal CA3-predominant damage and short
latency epileptogenesis after intra-amygdala microinjection of
kainic acid in mice. Brain Res. 1213, 140–151.
Mukai, F., Ishiguro, K., Sano, Y., Fujita, S.C., 2002. Alternative
splicing isoform of tau protein kinase I/glycogen synthase
kinase 3beta. J. Neurochem. 81, 1073–1083.Patrick, G.N., Zukerberg, L., Nikolic, M., delaMonte, S., Dikkes, P.,
Tsai, L.H., 1999. Conversion of p35 to p25 deregulates Cdk5
activity and promotes neurodegeneration. Nature 402,
615–622.
Peineau, S., Taghibiglou, C., Bradley, C., Wong, T.P., Liu, L., Lu, J.,
Lo, E., Wu, D., Saule, E., Bouschet, T., Matthews, P., Isaac, J.T.,
Bortolotto, Z.A., Wang, Y.T., Collingridge, G.L., 2007. LTP
inhibits LTD in the hippocampus via regulation of GSK3beta.
Neuron 53, 703–717.
Woodgett, J.R., 1990. Molecular cloning and expression of
glycogen synthase kinase-3/factor A. EMBO J. 9, 2431–2438.
Yang, J., Houk, B., Shah, J., Hauser, K.F., Luo, Y., Smith, G.,
Schauwecker, E., Barnes, G.N., 2005. Genetic background
regulates semaphorin gene expression and epileptogenesis in
mouse brain after kainic acid status epilepticus. Neuroscience
131, 853–869.
Zhang, Z., Larner, S.F., Liu, M.C., Zheng, W., Hayes, R.L., Wang, K.
K., 2009. Multiple alphaII-spectrin breakdown products
distinguish calpain and caspase dominated necrotic and
apoptotic cell death pathways. Apoptosis 14, 1289–1298.
